Multi-omics monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission

Shinya Tasaki, Katsuya Suzuki, Yoshiaki Kassai, Masaru Takeshita, Atsuko Murota, Yasushi Kondo, Tatsuya Ando, Yusuke Nakayama, Yuumi Okuzono, Maiko Takiguchi, Rina Kurisu, Takahiro Miyazaki, Keiko Yoshimoto, Hidekata Yasuoka, Kunihiro Yamaoka, Rimpei Morita, Akihiko Yoshimura, Hiroyoshi Toyoshiba () and Tsutomu Takeuchi ()
Additional contact information
Shinya Tasaki: Takeda Pharmaceutical Company Limited
Katsuya Suzuki: Keio University School of Medicine
Yoshiaki Kassai: Takeda Pharmaceutical Company Limited
Masaru Takeshita: Keio University School of Medicine
Atsuko Murota: Keio University School of Medicine
Yasushi Kondo: Keio University School of Medicine
Tatsuya Ando: Takeda Pharmaceutical Company Limited
Yusuke Nakayama: Takeda Pharmaceutical Company Limited
Yuumi Okuzono: Takeda Pharmaceutical Company Limited
Maiko Takiguchi: Takeda Pharmaceutical Company Limited
Rina Kurisu: Takeda Pharmaceutical Company Limited
Takahiro Miyazaki: Takeda Pharmaceutical Company Limited
Keiko Yoshimoto: Keio University School of Medicine
Hidekata Yasuoka: Keio University School of Medicine
Kunihiro Yamaoka: Keio University School of Medicine
Rimpei Morita: Keio University School of Medicine
Akihiko Yoshimura: Keio University School of Medicine
Hiroyoshi Toyoshiba: Takeda Pharmaceutical Company Limited
Tsutomu Takeuchi: Keio University School of Medicine

Nature Communications, 2018, vol. 9, issue 1, 1-12

Abstract: Abstract Sustained clinical remission (CR) without drug treatment has not been achieved in patients with rheumatoid arthritis (RA). This implies a substantial difference between CR and the healthy state, but it has yet to be quantified. We report a longitudinal monitoring of the drug response at multi-omics levels in the peripheral blood of patients with RA. Our data reveal that drug treatments alter the molecular profile closer to that of HCs at the transcriptome, serum proteome, and immunophenotype level. Patient follow-up suggests that the molecular profile after drug treatments is associated with long-term stable CR. In addition, we identify molecular signatures that are resistant to drug treatments. These signatures are associated with RA independently of known disease severity indexes and are largely explained by the imbalance of neutrophils, monocytes, and lymphocytes. This high-dimensional phenotyping provides a quantitative measure of molecular remission and illustrates a multi-omics approach to understanding drug response.

Date: 2018
References: Add references at CitEc
Citations: View citations in EconPapers (5)

Downloads: (external link)
https://www.nature.com/articles/s41467-018-05044-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:9:y:2018:i:1:d:10.1038_s41467-018-05044-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-018-05044-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().